Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001193805-20-000670
Filing Date
2020-06-08
Accepted
2020-06-08 17:10:39
Documents
4
Group Members
DEERFIELD HEALTHCARE INNOVATIONS FUND, L.P.DEERFIELD MANAGEMENT COMPANY, L.P.DEERFIELD MGMT HIF, L.P.DEERFIELD MGMT III, L.P.DEERFIELD MGMT IV, L.P.DEERFIELD PRIVATE DESIGN FUND III, L.P.DEERFIELD PRIVATE DESIGN FUND IV, L.P.

Document Format Files

Seq Description Document Type Size
1 e619689_sc13d-lt.htm SC 13D 176977
2 e619689_ex-99a.htm EX-99.(A) 15697
3 e619689_ex-99b.htm EX-99.(B) 124238
4 e619689_ex-99c.htm EX-99.(C) 29504
  Complete submission text file 0001193805-20-000670.txt   348184
Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Filed by) CIK: 0001352546 (see all company filings)

Type: SC 13D

Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Subject) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88225 | Film No.: 20949883
SIC: 2834 Pharmaceutical Preparations